The FDA’s plan to fast-track Pfizer‘s COVID-19 vaccine for children under 5 years old (24 million kids) was delayed because
“there’s a low number of cases overall in the clinical trial most kids are not getting symptomatic COVID as such one case in one direction or another can tip the perception of the vaccines overall defectiveness”
says Pfizer director (former FDA commissioner) Dr. Scott Gottlieb